Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 14Neoplasms 10Thoracic Neoplasms 3Carcinoma 3Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms, Nerve Tissue 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2NSCLC 2Meningeal Carcinomatosis 2Lung Diseases 2Colorectal Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Brain Neoplasms 2Adenocarcinoma 2Solid Tumor, Adult 1Renal Insufficiency 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Noonan Syndrome 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma, Malignant 1Lung Cancer Metastatic 1Lethal Congenital Contracture Syndrome 2 1Hemangioendothelioma, Epithelioid 1Head and Neck Neoplasms 1

Interventions

aflutinib 3osimertinib 2Radiotherapy 2tipifarnib 1apatinib 1Radiosurgery 1Immune Checkpoint Inhibitors 1Gefitinib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × NSCLC × osimertinib × Clear all
NCT06362980 2024-07-10

EGFR

National Cancer Center, China

Phase 1 Recruiting
20 enrolled
Thoracic

NSCLC

NCT05693090 2023-03-06

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Kura Oncology, Inc.

Phase 1 Withdrawn
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡